A Phase 3 interventional study of BG00012 (dimethyl fumarate) and BG00012 placebo in Healthy, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-13.
Sponsored by Biogen · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate whether premedication with 325 mg microcoated aspirin (ASA) tablet or a slow-titration dosing schedule of BG00012 reduces the incidence and severity of flushing and GI events following oral administration of BG00012 dosed at 240 mg twice a day (BID) in healthy volunteers. The secondary objective of this study is to evaluate the safety and tolerability of BG00012 when administered orally as a 240 mg BID dose regimen with and without 325 mg ASA premedication or following a slow-titration dosing schedule in healthy volunteers.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA placebo
Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
Drug: BG00012 placebo · Drug: ASA placebo
Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA
Participants received BG00012 for 8 weeks (120 mg once daily \[QD\] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
Drug: BG00012 (dimethyl fumarate) · Drug: BG00012 placebo · Drug: ASA placebo
Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
Also known as: BG-12, oral fumarate, DMF
Placebo matching BG00012
325 mg microcoated aspirin (ASA)
Also known as: acetylsalicylic acid, aspirin
Placebo matching aspirin
Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Flushing Severity Scale (MFSS)
Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
Time frame: Day 1 to Week 8
Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 (Combined), as Assessed by MFSS
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
Time frame: Week 1 to Week 4
Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 (Combined), as Assessed by MFSS
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
Time frame: Week 5 to Week 8
Worst Severity Scores of Overall Flushing During Weeks 1 to 4 of Treatment (Combined), as Assessed by MFSS
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
Time frame: Day 1 to Week 4
Worst Severity Scores of Overall Flushing During Weeks 5 to 8 of Treatment (Combined), as Assessed by MFSS
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
Time frame: Week 5 to Week 8
Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)
Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.
Time frame: Day 2 to Week 8
Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS
Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.
Time frame: Day 2 to Week 4
Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS
Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score.
Time frame: Week 5 to Week 8
Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS)
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
Time frame: Day 1 to Week 8
Percentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
Time frame: Day 1 to Week 4
Percentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
Time frame: Week 5 to Week 8
Worst Severity Scores of Acute GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
Time frame: Day 1 to Week 4
Worst Severity Scores of Acute GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
Time frame: Week 5 to Week 8
Percentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
Time frame: Day 1 to Week 8
Percentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
Time frame: Week 1 to Week 4
Percentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS)
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
Time frame: Week 5 to Week 8
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious AEs (SAEs)
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened.
Time frame: Day 1 up to end of Safety Follow-up (9 weeks)
Clinical Laboratory Shifts From Baseline in Reported Values: Hematology
Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute
Time frame: Day 1 to Week 8
Clinical Laboratory Shifts From Baseline in Reported Values: Blood Chemistry
Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen.
Time frame: Day 1 to Week 8
Clinical Laboratory Shifts From Baseline in Reported Values: Urinalysis
Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells.
Time frame: Day 1 to Week 8
Number of Participants With Abnormalities in Vital Signs
↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute
Time frame: Day 1 to Week 8
Number of Participants With Shifts From Baseline in Electrocardiogram (ECG) Results
Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.'
Time frame: Day 1 to Week 8
Duration of Flushing Events During the Overall Treatment Period, Based on MFSS
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
Time frame: Day 1 to Week 8
Duration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
Time frame: Week 1 to Week 4
Duration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
Time frame: Week 5 to Week 8
Duration of Acute GI Episodes During the Overall Treatment Period, Based on MAGISS
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
Time frame: Day 1 to Week 8
Duration of Acute GI Episodes During Weeks 1 to 4 (Combined), Based on MAGISS
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
Time frame: Week 1 to Week 4
Duration of Acute GI Episodes During Weeks 5 to 8 (Combined), Based on MAGISS
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
Time frame: Week 5 to Week 8
| Milestone | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Started | 44 | 44 | 43 | 42 |
| Completed | 39 | 36 | 36 | 30 |
| Not completed | 5 | 8 | 7 | 12 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 | 0 |
| Withdrew: Withdrew due to adverse event | 2 | 4 | 6 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 | 0 | 7 |
| Withdrew: Withdrawal by physician | 1 | 0 | 1 | 1 |
Participant-reported flushing side effect events during the treatment period recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Overall flushing events | 41 | 91 | 81 | 98 |
| Overall redness events | 27 | 86 | 77 | 90 |
| Overall warmth events | 41 | 93 | 84 | 98 |
| Overall tingling events | 23 | 88 | 67 | 86 |
| Overall itching events | 20 | 86 | 72 | 98 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Overall flushing events | 41 | 86 | 72 | 98 |
| Overall redness events | 25 | 81 | 63 | 88 |
| Overall warmth events | 41 | 88 | 67 | 95 |
| Overall tingling events | 23 | 84 | 51 | 83 |
| Overall itching events | 16 | 77 | 56 | 95 |
Participant-reported flushing side effect events during Weeks 1 to 4 recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Overall flushing events | 24 | 86 | 72 | 85 |
| Overall redness events | 15 | 78 | 64 | 79 |
| Overall warmth events | 17 | 86 | 75 | 82 |
| Overall tingling events | 15 | 81 | 64 | 70 |
| Overall itching events | 22 | 78 | 58 | 61 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin. This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
| units on a scale | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Overall flushing | 1.2 ± 1.70 | 4.4 ± 2.68 | 2.4 ± 2.26 | 5.6 ± 2.24 |
| Redness | 0.7 ± 1.33 | 3.8 ± 2.76 | 1.6 ± 1.75 | 5.1 ± 2.93 |
| Warmth | 1.2 ± 1.76 | 4.0 ± 2.55 | 2.3 ± 2.17 | 5.2 ± 2.37 |
| Tingling | 0.5 ± 1.00 | 3.4 ± 2.21 | 1.6 ± 2.13 | 4.0 ± 2.62 |
| Itching | 0.5 ± 1.21 | 3.2 ± 2.45 | 1.3 ± 1.72 | 4.3 ± 2.10 |
Worst severity of participant-reported flushing events during Weeks 1-4 of treatment combined, recorded on the eDiary as assessed by MFSS. MFSS questionnaire measures the side effects related to flushing following drug administration. Flushing means redness, warmth, tingling or itching of the skin.This questionnaire relates only to the period of time since the investigational drug was administered and was to be completed within 10 hours of taking the study drug (2 times/day). Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects).
| units on a scale | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Overall flushing | 0.9 ± 1.67 | 3.8 ± 2.48 | 3.3 ± 2.78 | 3.1 ± 2.26 |
| Redness | 0.4 ± 1.14 | 3.6 ± 2.73 | 2.9 ± 2.67 | 2.9 ± 2.30 |
| Warmth | 0.8 ± 1.79 | 3.9 ± 2.53 | 3.1 ± 2.50 | 2.9 ± 2.15 |
| Tingling | 0.3 ± 0.82 | 3.3 ± 2.50 | 2.3 ± 2.36 | 2.2 ± 1.96 |
| Itching | 0.7 ± 1.58 | 3.1 ± 2.71 | 2.3 ± 2.52 | 1.8 ± 2.04 |
Participant-reported flushing events during the overall treatment period, recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period, as Assessed by the Modified Global Flushing Severity Scale (MGFSS) | 43 | 86 | 74 | 93 |
Participant-reported flushing events during Weeks 1 to 4 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to events reported in the 24 hours after the first dose on Day 1.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting Overall Flushing Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MGFSS | 41 | 84 | 62 | 90 |
Participant-reported flushing events during Weeks 5 to 8 of treatment (combined), recorded on the hand-held participant reporting device (eDiary) as assessed by MGFSS. The MGFSS measures the side effects related to flushing during the past 24 hours. Flushing means redness, warmth, tingling or itching of the skin. Each question is rated on a scale from 0 (no flushing side effects) to 10 (extreme flushing side effects). Day 1 data are not included in the analysis because MGFSS question refers to last 24 hours flushing score.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting Overall Flushing Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MGFSS | 24 | 86 | 67 | 85 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period, as Assessed by the Modified Acute Gastrointestinal Scale (MAGISS) | 73 | 81 | 81 | 86 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting GI Events During Weeks 1 to 4 of Treatment (Combined), as Assessed by MAGISS | 66 | 81 | 79 | 79 |
The MAGISS is a participant-reported questionnaire about side effects of the gastrointestinal system following drug administration, and is based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms. A participant was considered having overall GI side effect if he/she had a score of \>=1 for at least one of the GI side effects including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating and flatulence.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting GI Events During Weeks 5 to 8 of Treatment (Combined), as Assessed by MAGISS | 41 | 59 | 53 | 61 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
| units on a scale | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Nausea | 0.7 ± 1.59 | 1.6 ± 2.41 | 1.6 ± 2.54 | 1.5 ± 2.09 |
| Diarrhea | 1.0 ± 1.97 | 1.8 ± 2.47 | 1.5 ± 2.76 | 1.0 ± 1.67 |
| Upper abdominal pain | 0.8 ± 1.38 | 1.1 ± 2.16 | 1.7 ± 2.71 | 1.4 ± 2.47 |
| Lower abdominal pain | 0.5 ± 1.21 | 1.4 ± 2.14 | 1.3 ± 2.32 | 1.2 ± 2.12 |
| Vomiting | 0.2 ± 0.75 | 0.3 ± 1.28 | 0.3 ± 1.63 | 0.2 ± 1.10 |
| Indigestion | 0.7 ± 1.29 | 0.9 ± 1.83 | 0.6 ± 1.26 | 0.9 ± 1.97 |
| Constipation | 0.4 ± 1.45 | 0.9 ± 2.23 | 0.6 ± 1.45 | 0.9 ± 1.85 |
| Bloating | 0.5 ± 1.17 | 1.1 ± 1.96 | 1.3 ± 2.08 | 1.0 ± 1.88 |
| Flatulence | 1.3 ± 1.73 | 1.3 ± 2.03 | 1.4 ± 1.76 | 1.6 ± 2.20 |
Severity of GI-related events using the MAGISS to measure GI symptoms (nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, flatulence), based on a 0- to 10-point scale, with 0 representing absence of symptoms and 10 representing the most severe symptoms.
| units on a scale | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Nausea | 0.4 ± 1.51 | 0.9 ± 1.79 | 0.8 ± 1.94 | 0.9 ± 1.65 |
| Diarrhea | 1.0 ± 2.01 | 1.4 ± 2.29 | 0.8 ± 2.13 | 0.7 ± 1.42 |
| Upper abdominal pain | 0.6 ± 1.69 | 0.5 ± 1.50 | 0.4 ± 1.21 | 0.6 ± 1.56 |
| Lower abdominal pain | 0.6 ± 1.48 | 0.4 ± 1.42 | 0.5 ± 1.38 | 0.9 ± 1.72 |
| Vomiting | 0.2 ± 1.41 | 0.1 ± 0.82 | 0.1 ± 0.83 | 0.0 ± 0.00 |
| Indigestion | 0.4 ± 1.26 | 0.5 ± 1.32 | 0.5 ± 1.38 | 0.4 ± 1.06 |
| Constipation | 0.4 ± 1.20 | 0.1 ± 0.59 | 0.6 ± 1.63 | 0.3 ± 1.05 |
| Bloating | 0.5 ± 1.23 | 0.7 ± 1.61 | 0.7 ± 1.55 | 0.8 ± 1.52 |
| Flatulence | 0.8 ± 1.65 | 1.2 ± 2.04 | 0.4 ± 1.08 | 0.9 ± 1.54 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting GI Events During the Overall Treatment Period, as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS) | 59 | 70 | 79 | 79 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting GI Events During Weeks 1 to 4 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS) | 57 | 65 | 67 | 71 |
The MOGISS is a questionnaire about overall side effects related to the gastrointestinal system (including nausea, diarrhea, upper abdominal pain, lower abdominal pain, vomiting, indigestion, constipation, bloating, and flatulence) during the 24 hours prior to each AM dose. Participants were to answer the questions at the same time each day, before the morning drug administration.
| percentage of participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Percentage of Participants Reporting GI Events During Weeks 5 to 8 (Combined), as Assessed by the Modified Overall Gastrointestinal Symptom Scale (MOGISS) | 34 | 59 | 50 | 58 |
AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the subject at immediate risk of death; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the subject or may require intervention to prevent one of the other outcomes. An AE was considered treatment-emergent if it occurred after the start of study treatment or was present prior to the start of study treatment but subsequently worsened.
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Any event | 24 | 24 | 26 | 26 |
| Moderate or severe event | 10 | 13 | 12 | 11 |
| Severe event | 0 | 4 | 4 | 1 |
| Related event | 8 | 17 | 16 | 18 |
| Serious event | 0 | 1 | 0 | 0 |
| Discontinuation of treatment due to an event | 2 | 4 | 6 | 3 |
| Withdrawal from study due to an event | 2 | 4 | 6 | 3 |
Number of participants with clinical laboratory shifts from baseline in hematology values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. abs=absolute
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| White blood cells: shift to low; n=43, 43, 43, 41 | 0 | 2 | 0 | 0 |
| White blood cells: shift to high; n=44, 43, 43, 42 | 0 | 0 | 1 | 0 |
| Neutrophils abs: shift to low; n=42, 42, 42, 41 | 3 | 6 | 2 | 2 |
| Neutrophils abs: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 1 |
| Lymphocytes abs: shift to low; n=43, 43, 43, 41 | 1 | 5 | 2 | 3 |
| Lymphocytes abs: shift to high; n=44, 43, 42, 42 | 0 | 0 | 0 | 0 |
| Monocytes abs: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Monocytes abs: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Eosinophils abs: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Eosinophils abs: shift to high; n=44, 43, 43, 42 | 0 | 5 | 6 | 6 |
| Basophils abs: shift to high; n=44, 43, 43, 42 | 0 | 1 | 1 | 0 |
| Red blood cells: shift to low; n=44, 43, 43, 40 | 0 | 2 | 0 | 0 |
| Red blood cells: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Hemoglobin: shift to low; n=43, 41, 43, 42 | 1 | 3 | 1 | 0 |
| Hemoglobin: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Hematocrit: shift to low; n=44, 43, 43, 42 | 0 | 2 | 0 | 0 |
| Hematocrit: shift to high; n=43, 43, 43, 42 | 0 | 0 | 0 | 1 |
| Platelets: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Platelets: shift to high; n=44, 41, 43, 42 | 0 | 0 | 1 | 1 |
Number of participants with clinical laboratory shifts from baseline in blood chemistry values. Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, GGT=gamma-glutamyl transferase, LDH=lactate dehydrogenase, BUN=blood urea nitrogen.
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| ALP: shift to high; n=44, 42, 43, 42 | 0 | 0 | 0 | 0 |
| ALT: shift to high; n=44, 42, 43, 42 | 1 | 2 | 5 | 2 |
| AST: shift to high; n=44, 43, 43, 41 | 2 | 3 | 4 | 1 |
| GGT: shift to high; n=44, 41, 43, 42 | 0 | 0 | 2 | 0 |
| LDH: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| LDH: shift to high; n=44, 43, 43, 42 | 0 | 0 | 1 | 0 |
| Total bilirubin: shift to high; n=44, 42, 42, 40 | 1 | 1 | 0 | 1 |
| BUN: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| BUN: shift to high; n=44, 43, 41, 42 | 1 | 0 | 1 | 1 |
| Creatinine: shift to low; n=44, 43, 43, 42 | 0 | 1 | 0 | 0 |
| Creatinine: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Uric Acid: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Uric Acid: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Sodium: shift to low; n=44, 43, 43, 42 | 1 | 0 | 0 | 0 |
| Sodium: shift to high; n=44, 43, 43, 42 | 0 | 0 | 1 | 0 |
| Potassium: shift to low: n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Potassium: shift to high: n=44, 42, 42, 41 | 1 | 1 | 1 | 0 |
| Chloride: shift to low; n=44, 43, 43, 42 | 1 | 0 | 0 | 0 |
| Chloride: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Bicarbonate: shift to low; n=44, 43, 43, 42 | 1 | 1 | 1 | 0 |
| Bicarbonate: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Calcium: shift to low; n=44, 42, 43, 42 | 0 | 0 | 1 | 0 |
| Calcium: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Glucose: shift to low; n=43, 43, 41, 41 | 3 | 1 | 1 | 2 |
| Glucose: shift to high; n=44, 43, 43, 42 | 1 | 0 | 0 | 0 |
| Magnesium: shift to low; n=44, 43, 43, 42 | 1 | 0 | 0 | 1 |
| Magnesium: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Phosphorus: shift to low; n=44, 43, 43, 41 | 0 | 1 | 0 | 0 |
| Phosphorus: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 1 |
| Albumin: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Albumin: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Direct bilirubin: shift to high; n=44, 43, 43, 40 | 0 | 0 | 0 | 0 |
| Total protein: shift to low; n=44, 41, 43, 41 | 0 | 0 | 1 | 0 |
| Total protein: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory shifts from baseline in urinalysis values.Shift to low includes normal to low, high to low, and unknown to low. Shift to high includes normal to high, low to high, and unknown to high. Shift to positive includes negative to positive and unknown to positive. RBC=red blood cells, WBC=white blood cells.
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Specific gravity: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Specific gravity: shift to high; n=44, 42, 43, 42 | 0 | 0 | 2 | 0 |
| pH: shift to low; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| pH: shift to high; n=44, 43, 43, 42 | 0 | 0 | 0 | 0 |
| Blood: shift to positive; n=42, 39, 39, 42 | 3 | 6 | 1 | 2 |
| Color: shift to positive; n=41, 43, 41, 39 | 2 | 1 | 4 | 5 |
| Glucose: shift to positive; n=44, 43, 43, 41 | 0 | 2 | 1 | 0 |
| Ketones: shift to positive; n=44, 43, 43, 42 | 1 | 7 | 9 | 6 |
| Protein: shift to positive; n=44, 41, 43, 41 | 0 | 1 | 1 | 1 |
| Microscopic RBC; n=44, 40, 40, 41 | 3 | 4 | 1 | 2 |
| Microscopic WBC; n=43, 40, 41, 42 | 4 | 9 | 3 | 3 |
↑=increase; ↓=decrease; BL=baseline; bpm=beats per minute; SBP=systolic blood pressure; DBP=diastolic blood pressure; b/m=breaths per minute
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Temperature >38°C + ↑ from BL of ≥1°C | 0 | 0 | 0 | 0 |
| Pulse >120 bpm or ↑ from BL of >20 bpm | 8 | 10 | 20 | 17 |
| Pulse <50 bpm or ↓ from BL of >20 bpm | 11 | 4 | 3 | 4 |
| SBP >180 mm Hg or ↑ from BL of >40 mm Hg | 1 | 0 | 0 | 0 |
| SBP <90 mm Hg or ↓ from BL of >30 mm Hg | 1 | 2 | 1 | 1 |
| DBP >105 mm Hg or ↑ from BL of >30 mm Hg | 0 | 0 | 0 | 0 |
| DBP <50 mm Hg or ↓ from BL of >20 mm Hg | 1 | 3 | 0 | 1 |
| Respiration rate >25 b/m or ↑ from BL of ≥50% | 1 | 2 | 3 | 3 |
| Respiration rate 10 b/m or ↓ from BL of ≥50% | 0 | 0 | 0 | 0 |
Shift to 'abnormal, not adverse event' includes unknown or normal to 'abnormal, not adverse event.' Shift to 'abnormal, adverse event' includes unknown or normal to 'abnormal, adverse event.'
| participants | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Shift to abnormal, not adverse event | 2 | 3 | 2 | 4 |
| Shift to abnormal, adverse event | 0 | 0 | 0 | 0 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
| minutes | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Duration of Flushing Events During the Overall Treatment Period, Based on MFSS | 98.4 ± 92.04 | 63.2 ± 34.55 | 69.8 ± 78.09 | 68.9 ± 52.82 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
| minutes | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Duration of Flushing Events During the Weeks 1 to 4 (Combined), Based on MFSS | 117.6 ± 143.90 | 67.6 ± 43.83 | 89.8 ± 140.67 | 69.2 ± 53.00 |
For participants with more than 1 flushing episode during a visit interval, the average duration for the visit interval was used. The average duration is calculated as: the total duration of all flushing episodes / the total number of flushing episodes.
| minutes | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Duration of Flushing Events During the Weeks 5 to 8 (Combined), Based on MFSS | 113.2 ± 160.82 | 55.7 ± 32.37 | 73.2 ± 66.34 | 56.0 ± 35.79 |
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
| hours | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Nausea; n=12, 21, 21, 22 | 9.74 ± 17.008 | 7.05 ± 10.498 | 10.01 ± 18.283 | 2.98 ± 3.247 |
| Diarrhea; n=20, 20 17, 15 | 5.57 ± 10.037 | 2.92 ± 3.329 | 14.66 ± 32.686 | 4.97 ± 9.687 |
| Upper abdominal pain; n=17, 14, 19, 19 | 19.08 ± 46.873 | 6.67 ± 16.916 | 15.88 ± 25.307 | 3.83 ± 5.712 |
| Lower abdominal pain; n=12, 19, 17, 16 | 6.65 ± 5.307 | 13.93 ± 26.850 | 10.84 ± 16.312 | 7.75 ± 10.456 |
| Vomiting; n=3, 3, 3, 2 | 5.87 ± 5.033 | 10.08 ± 8.755 | 1.88 ± 2.717 | 0.75 ± 0.707 |
| Indigestion; n=12, 13, 12, 12 | 4.76 ± 8.203 | 16.49 ± 28.865 | 3.80 ± 2.543 | 4.91 ± 8.263 |
| Constipation; n=6, 8, 13, 11 | 20.49 ± 12.040 | 28.20 ± 35.425 | 14.26 ± 9.783 | 20.90 ± 18.060 |
| Bloating; n=14, 14, 21, 12 | 9.50 ± 9.066 | 16.91 ± 27.128 | 9.68 ± 10.108 | 77.24 ± 125.961 |
| Flatulence; n=23, 20, 22, 20 | 16.41 ± 44.149 | 9.06 ± 9.626 | 68.93 ± 290.248 | 63.84 ± 180.597 |
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
| hours | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Nausea; n=10, 18, 18, 20 | 10.47 ± 18.678 | 7.23 ± 10.916 | 11.18 ± 19.568 | 2.86 ± 3.359 |
| Diarrhea; n=13, 20, 14, 14 | 5.20 ± 11.309 | 2.53 ± 3.013 | 16.04 ± 35.945 | 4.97 ± 10.074 |
| Upper abdominal pain; n=14, 14, 17, 15 | 21.37 ± 51.620 | 6.81 ± 16.876 | 17.65 ± 26.294 | 4.31 ± 6.350 |
| Lower abdominal pain; n=9, 18, 14, 13 | 5.40 ± 4.658 | 14.20 ± 27.637 | 12.51 ± 17.621 | 6.30 ± 6.080 |
| Vomiting; n=2, 2, 2, 2 | 4.31 ± 5.999 | 5.63 ± 5.834 | 2.53 ± 3.500 | 0.75 ± 0.707 |
| Indigestion; n=11, 11, 9, 11 | 5.08 ± 8.552 | 29.00 ± 48.416 | 3.93 ± 2.873 | 5.05 ± 8.665 |
| Constipation; n=4, 8, 11, 11 | 17.05 ± 7.452 | 27.61 ± 35.177 | 15.12 ± 7.761 | 21.28 ± 19.298 |
| Bloating; n=9, 14, 19, 11 | 6.70 ± 6.792 | 13.81 ± 25.321 | 11.07 ± 10.631 | 95.69 ± 186.884 |
| Flatulence; n=21, 17, 22, 19 | 12.83 ± 27.948 | 9.34 ± 12.946 | 35.86 ± 134.748 | 61.13 ± 168.572 |
Duration is calculated as follows: \[(GI side effect) end date/time - (GI side effect) start date/time\]/3600. For GI side effects with no end date, the end date is imputed using the last diary date/time. For subjects with more than 1 GI episode during a visit interval, the average duration for the study visit interval is used. The average duration is calculated as the total duration of the GI side effect / the total number of GI side effects.
| hours | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Nausea; n=4, 9, 6, 9 | 3.96 ± 3.668 | 4.34 ± 6.256 | 2.66 ± 1.390 | 2.34 ± 1.904 |
| Diarrhea; n=12, 13, 6, 8 | 4.50 ± 6.389 | 6.62 ± 12.782 | 7.05 ± 8.002 | 2.14 ± 2.007 |
| Upper abdominal pain; n=6, 5, 5, 5 | 5.29 ± 5.785 | 1.12 ± 0.965 | 1.86 ± 1.491 | 1.73 ± 1.440 |
| Lower abdominal pain; n=7, 5, 5, 9 | 6.63 ± 7.739 | 3.98 ± 3.516 | 2.84 ± 1.477 | 22.54 ± 61.180 |
| Vomiting; n=1, 1, 1, 0 | 9.00 ± NA | 19.00 ± NA | 0.58 ± NA | NA ± NA |
| Indigestion; n=6, 7, 7, 5 | 2.43 ± 1.569 | 2.57 ± 2.586 | 5.02 ± 6.944 | 1.63 ± 1.101 |
| Constipation; n=5, 2, 4, 4 | 23.35 ± 17.110 | 15.47 ± 21.143 | 21.30 ± 23.181 | 18.24 ± 8.644 |
| Bloating; n=7, 8, 7, 8 | 12.49 ± 10.595 | 18.52 ± 25.682 | 4.16 ± 3.018 | 85.64 ± 115.872 |
| Flatulence; n=9, 13, 7, 10 | 44.67 ± 112.426 | 7.21 ± 10.051 | 105.86 ± 275.125 | 18.48 ± 26.347 |
Collected over AEs: from the administration of the first dose of study treatment to the Safety Follow-up (approximately 9 weeks). SAEs: from signing of informed consent to the Safety Follow-up (up to approximately 13 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/44 (0%) | 5/44 (11.4%) |
| BG00012 | — | 1/43 (2.3%) | 12/43 (27.9%) |
| BG00012 + ASA | — | 0/43 (0%) | 15/43 (34.9%) |
| BG00012 Slow Titration | — | 0/42 (0%) | 12/42 (28.6%) |
| Event | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| Ovarian germ cell teratoma stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/44 | 1/43 | 0/43 | 0/42 |
| Event | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration |
|---|---|---|---|---|
| HeadacheNervous system disorders | 4/44 | 9/43 | 2/43 | 9/42 |
| Upper respiratory tract infectionInfections and infestations | 1/44 | 3/43 | 7/43 | 1/42 |
| DiarrhoeaGastrointestinal disorders | 0/44 | 2/43 | 5/43 | 0/42 |
| EosinophiliaBlood and lymphatic system disorders | 0/44 | 1/43 | 3/43 | 2/42 |
| Abdominal painGastrointestinal disorders | 0/44 | 0/43 | 3/43 | 0/42 |
| VomitingGastrointestinal disorders | 0/44 | 2/43 | 3/43 | 0/42 |
All randomized and treated participants
| Age, Continuous(years) | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration | Total |
|---|---|---|---|---|---|
| Mean | 35.5 ± 8.78 | 39.0 ± 9.61 | 38.1 ± 10.29 | 36.2 ± 9.33 | 37.2 ± 9.54 |
| Age, Customized(participants) | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration | Total |
|---|---|---|---|---|---|
| 25 to 34 years | 22 | 19 | 17 | 21 | 79 |
| 35 to 44 years | 13 | 7 | 13 | 10 | 43 |
| 45 to 55 years | 9 | 17 | 13 | 11 | 50 |
| Sex: Female, Male(Participants) | Placebo | BG00012 | BG00012 + ASA | BG00012 Slow Titration | Total |
|---|---|---|---|---|---|
| Female | 14 | 21 | 17 | 20 | 72 |
| Male | 30 | 22 | 26 | 22 | 100 |
The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate